SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ:SRNE) (“Sorrento”), and its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), received approval from the U.S. Food and Drug Administration…Original Article
You may also like
Apellis Announces U.S. FDA Approval of the Empaveli...
FDA Approves Technegas (Technetium Tc 99-m Labeled...
FDA Approves Rivfloza (nedosiran) for the Treatment of...
FDA Approves Tofidence (tocilizumab-bavi), a...
FDA Approves Exxua (gepirone) for the Treatment of...
FDA Approves Pombiliti (cipaglucosidase alfa-atga) +...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.